Cure My Disease

Don't miss your cure!

 Log in / Sign up

Four-in-One imaging may predict breast cancer treatment success

NCT ID NCT06879704

Recruiting now Knowledge-focused Sponsor: Centre Henri Becquerel Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether combining four types of scans (ultrasound, mammography, MRI, and PET-CT) can accurately predict if triple-negative breast cancer has been completely eliminated by chemotherapy and immunotherapy. Researchers will also check blood markers to identify which patients benefit most or are at higher risk for side effects. About 115 adults aged 18-75 with early-stage triple-negative breast cancer will participate.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE NEGATIVE BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Centre Henri Becquerel

    RECRUITING

    Rouen, 76038, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.